Central serous chorioretinopathy: A review of epidemiology and pathophysiology

Clinical and Experimental Ophthalmology

Volumn 41, Issue 2, 2013, Pages 201-214

  Liew, Gerald ^a,b   Quin, Godfrey ^a   Gillies, Mark ^a   Fraser Bell, Samantha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Central serous chorioretinopathy; Epidemiology; Pathogenesis

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; GLUCOCORTICOID; KETOCONAZOLE; MIFEPRISTONE; SILDENAFIL; STRESS HORMONE; TADALAFIL; VERTEPORFIN;

ARGON LASER; CENTRAL SEROUS RETINOPATHY; COLLAGEN DISEASE; CUSHING SYNDROME; DIODE LASER; FAMILY HISTORY; HELICOBACTER PYLORI; HUMAN; HYPERTENSION; MEDICAL HISTORY; MEDICAL LITERATURE; MEDLINE; MICROPULSE DIODE LASER; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PREGNANCY; PROGNOSIS; PSYCHOSOMATIC DISORDER; RESPIRATORY TRACT ALLERGY; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; TYPE A BEHAVIOR; VASCULAR DISEASE; VISUAL ACUITY;

BLINDNESS; CENTRAL SEROUS CHORIORETINOPATHY; HUMANS; INCIDENCE; RISK FACTORS;

EID: 84875483932     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02848.x     Document Type: Review

References (134)

1. Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126-45.
2. Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. Retina 1987; 7: 111-31.
3. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967; 63 (Suppl.): 1-139.
4. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008; 115: 169-73.
5. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011; 22: 166-73.
6. Spaide RF, Campeas L, Haas A etal. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-9.
7. Gackle HC, Lang GE, Freissler KA, Lang GK. [Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects]. Ophthalmologe 1998; 95: 529-33.
8. How AC, Koh AH. Angiographic characteristics of acute central serous chorioretinopathy in an Asian population. Ann Acad Med Singapore 2006; 35: 77-9.
9. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR. Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003; 95: 553-9.
10. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845.
11. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993; 111: 1229-33.
12. Quillen DA, Gass DM, Brod RD, Gardner TW, Blankenship GW, Gottlieb JL. Central serous chorioretinopathy in women. Ophthalmology 1996; 103: 72-9.
13. Sunness JS, Haller JA, Fine SL. Central serous chorioretinopathy and pregnancy. Arch Ophthalmol 1993; 111: 360-4.
14. Gass JD. Central serous chorioretinopathy and white subretinal exudation during pregnancy. Arch Ophthalmol 1991; 109: 677-81.
15. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004; 111: 244-9.
16. Tittl MK, Spaide RF, Wong D etal. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999; 128: 63-8.
17. Cunningham ET, Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology 1996; 103: 2081-90.
18. Sharma OP, Rao N, Roy M. Sarcoidosis and central serous retinopathy: a dangerous combination. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 189-91.
19. Khng CGYW, Yap EY, Au-Eong KG, Lim TH, Leong KH. Central serous retinopathy complicating systemic lupus erythematosus: a case series. Clin Experiment Ophthalmol 2000; 28: 309-13.
20. Leveque TK, Yu L, Musch DC, Chervin RD, Zacks DN. Central serous chorioretinopathy and risk for obstructive sleep apnea. Sleep Breath 2007; 11: 253-7.
21. Cotticelli L, Borrelli M, D'Alessio AC etal. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol 2006; 16: 274-8.
22. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica 2001; 215: 183-7.
23. Park DW, Schatz H, Gaffney MM, McDonald HR, Johnson RN, Schaeffer D. Central serous chorioretinopathy in two families. Eur J Ophthalmol 1998; 8: 42-7.
24. Spahn C, Wiek J, Burger T. [Operationalized psychodynamic diagnostics (OPD) in patients with central serous chorioretinopathy]. Psychother Psychosom Med Psychol 2004; 54: 52-7.
25. Conrad R, Bodeewes I, Schilling G, Geiser F, Imbierowicz K, Liedtke R. [Central serous chorioretinopathy and psychological stress]. Ophthalmologe 2000; 97: 527-31.
26. Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry 1987; 144: 46-50.
27. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther 2006; 22: 145-9.
28. Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 704-8.
29. Sun J, Tan J, Wang Z, Yang H, Zhu X, Li L. Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 313-6.
30. Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997; 81: 962-4.
31. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003; 110: 698-703.
32. Harada T, Harada K. Six cases of central serous choroidopathy induced by systemic corticosteroid therapy. Doc Ophthalmol 1985; 60: 37-44.
33. Iannetti L, Spinucci G, Pesci FR, Vicinanza R, Stigliano A, Pivetti-Pezzi P. Central serous chorioretinopathy as a presenting symptom of endogenous Cushing syndrome: a case report. Eur J Ophthalmol 2011; 21: 661-4.
34. Thoelen AM, Bernasconi PP, Schmid C, Messmer EP. Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 2000; 20: 98-9.
35. Fawzi AA, Holland GN, Kreiger AE, Heckenlively JR, Arroyo JG, Cunningham ET, Jr. Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 2006; 113: 805-13.
36. Lee CS, Kang EC, Lee KS, Byeon SH, Koh HJ, Lee SC. Central serous chorioretinopathy after renal transplantation. Retina 2011; 31: 1896-903.
37. Fawzi AA, Cunningham ET, Jr. Central serous chorioretinopathy after bone marrow transplantation. Am J Ophthalmol 2001; 131: 804-5.
38. Karashima K, Fujioka S, Harino S. Two cases of central serous chorioretinopathy treated with photocoagulation after bone marrow transplantation. Retina 2002; 22: 651-3.
39. Cheng LL, Kwok AK, Wat NM, Neoh EL, Jon HC, Lam DS. Graft-vs-host-disease-associated conjunctival chemosis and central serous chorioretinopathy after bone marrow transplant. Am J Ophthalmol 2002; 134: 293-5.
40. Ebner R, DaCol E, Bullorsky E. True, true and related? Surv Ophthalmol 2001; 45: 489-92.
41. Carvalho-Recchia CA, Yannuzzi LA, Negrao S etal. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002; 109: 1834-7.
42. Jonas JB, Kamppeter BA. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol 2005; 89: 386-7.
43. Song E, Wakakura M, Ishikawa S. [Central serous chorioretinopathy induced by corticosteroids]. Nihon Ganka Gakkai Zasshi 1997; 101: 257-64.
44. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002; 47: 431-48.
45. Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol 1974; 77: 158-60.
46. Eckstein MB, Spalton DJ, Holder G. Visual loss from central serous retinopathy in systemic lupus erythematosus. Br J Ophthalmol 1993; 77: 607-9.
47. Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1225-8.
48. Jain AK, Kaines A, Schwartz S. Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1037-9.
49. Fraunfelder FW, Fraunfelder FT. Central serous chorioretinopathy associated with sildenafil. Retina 2008; 28: 606-9.
50. Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 2012; 227: 85-9.
51. Gordon-Bennett P, Rimmer T. Central serous chorioretinopathy following oral tadalafil. Eye (Lond) 2012; 26: 168-9.
52. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina 2011; 31: 332-5.
53. Kerr NM, Danesh-Meyer HV. Phosphodiesterase inhibitors and the eye. Clin Experiment Ophthalmol 2009; 37: 514-23.
54. French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 2010; 30: 271-4.
55. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses 2004; 63: 524-7.
56. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, Rafeey M, Ghorbanihaghjo A. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011; 17: 99-103.
57. Williams CM. Visual acuity and colour vision tests-a preliminary report. Br J Physiol Opt 1976; 31: 29-31.
58. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998; 46: 131-7.
59. Laatikainen L, Hoffren M. Long-term follow-up study of nonsenile detachment of the retinal pigment epithelium. Eur J Ophthalmol 1991; 1: 79-84.
60. Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992; 81: 379-86.
61. van Velthoven ME, Verbraak FD, Garcia PM, Schlingemann RO, Rosen RB, de Smet MD. Evaluation of central serous retinopathy with en face optical coherence tomography. Br J Ophthalmol 2005; 89: 1483-8.
62. Mitarai K, Gomi F, Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1415-20.
63. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-20.
64. Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001; 79: 417-21.
65. Loo RH, Scott IU, Flynn HW, Jr etal. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002; 22: 19-24.
66. Ooto S, Hangai M, Sakamoto A etal. High-resolution imaging of resolved central serous chorioretinopathy using adaptive optics scanning laser ophthalmoscopy. Ophthalmology 2010; 117: 1800-9.
67. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996; 114: 689-92.
68. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-34.
69. Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA. Acute central serous chorioretinopathy and fundus autofluorescence. Retina 2005; 25: 989-93.
70. Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984; 91: 1554-72.
71. Gomolin JE. Choroidal neovascularization and central serous chorioretinopathy. Can J Ophthalmol 1989; 24: 20-3.
72. Dickhoff KV, Hoffren M, Laatikainen L. [Retinal pigment epithelial changes related to central serous retinopathy]. J Fr Ophtalmol 1989; 12: 877-81.
73. Bandello F, Virgili G, Lanzetta P, Pirracchio A, Menchini U. [ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy)]. J Fr Ophtalmol 2001; 24: 448-51.
74. Mutlak JA, Dutton GN, Zeini M, Allan D, Wail A. Central visual function in patients with resolved central serous retinopathy. A long term follow-up study. Acta Ophthalmol (Copenh) 1989; 67: 532-6.
75. Maaranen T, Mantyjarvi M. Contrast sensitivity in patients recovered from central serous chorioretinopathy. Int Ophthalmol 1999; 23: 31-5.
76. Jalali S, Gupta A, Jain IS, Ram J. Visual prognosis in central serous choroidopathy: residual Amsler grid changes. Can J Ophthalmol 1991; 26: 270-2.
77. Mudvari SS, Goff MJ, Fu AD etal. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina 2007; 27: 1168-73.
78. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010; 24: 1743-56.
79. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S, Ravera G. Risk factors for posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 2008; 28: 1146-50.
80. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 2008; 28: 1008-12.
81. Piccolino FC, De La Longrais RR, Ravera G etal. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 2005; 139: 87-99.
82. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 2008; 27: 45-88.
83. Wang GH, Zhang J, Zhang D, Lv FL, Wang LX. Value of three-dimensional optical coherence tomography and fundus photochromy in correlating the fluorescein leaking sites of acute central serous chorioretinopathy. Med Princ Pract 2011; 20: 283-6.
84. Yu H, Xia GY, Gao MH, Yu J, Zhang YY. [Morphologic changes in acute central serous chorioretinopathy evaluated by spectral domain optical coherence tomography]. Zhonghua Yan Ke Za Zhi 2011; 47: 508-15.
85. Fujimoto H, Gomi F, Wakabayashi T, Sawa M, Tsujikawa M, Tano Y. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology 2008; 115: 1494-500.
86. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographic patterns in patients with central serous chorioretinopathy at the initial visit. Ophthalmologica 1992; 205: 69-76.
87. Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-4.
88. Negi A, Marmor MF. The resorption of subretinal fluid after diffuse damage to the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1983; 24: 1475-9.
89. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994; 112: 1057-62.
90. Tittl M, Maar N, Polska E, Weigert G, Stur M, Schmetterer L. Choroidal hemodynamic changes during isometric exercise in patients with inactive central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4717-21.
91. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986; 9: 37-41.
92. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34.
93. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci 2006; 47: 3474-8.
94. Regatieri CV, Branchini L, Fujimoto JG, Duker JS. Choroidal imaging using spectral-domain optical coherence tomography. Retina 2012; 32: 865-76.
95. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-73.
96. Kim SW, Oh J, Kwon SS, Yoo J, Huh K. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy. Retina 2011; 31: 1904-11.
97. Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (Lond) 2011; 25: 1635-40.
98. Jirarattanasopa P, Ooto S, Tsujikawa A etal. Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012; (forthcoming).
99. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina 1994; 14: 231-42.
100. Spaide R. Autofluorescence from the outer retina and subretinal space: hypothesis and review. Retina 2008; 28: 5-35.
101. Spaide RF, Klancnik JM, Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005; 112: 825-33.
102. von Ruckmann A, Fitzke FW, Fan J, Halfyard A, Bird AC. Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 2002; 133: 780-6.
103. Field MG, Elner VM, Park S etal. Detection of retinal metabolic stress resulting from central serous retinopathy. Retina 2009; 29: 1162-6.
104. Ahad MA, Chua CN, Evans NM. Central serous chorioretinopathy associated with testosterone therapy. Eye (Lond) 2006; 20: 503-5.
105. Grieshaber MC, Staub JJ, Flammer J. The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol 2007; 91: 118-9.
106. Rocha EM, Wickham LA, da Silveira LA etal. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 2000; 84: 76-84.
107. Zumoff B, Rosenfeld RS, Friedman M, Byers SO, Rosenman RH, Hellman L. Elevated daytime urinary excretion of testosterone glucuronide in men with the type A behavior pattern. Psychosom Med 1984; 46: 223-5.
108. Laudat MH, Guilhaume B, Blot P, Fournier C, Giauque JP, Luton JP. [The hormonal state of pregnancy: modification of cortisol and testosterone]. Ann Endocrinol (Paris) 1987; 48: 334-8.
109. Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina 2011; 31: 766-71.
110. Sharma T, Shah N, Rao M etal. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111: 1708-14.
111. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95: 457-66.
112. Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674-7.
113. Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004; 137: 1073-80.
114. Yannuzzi LA, Slakter JS, Gross NE etal. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23: 288-98.
115. Cardillo PF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003; 23: 752-63.
116. Lee TG, Kim JE. Photodynamic therapy for steroid-associated central serous chorioretinopathy. Br J Ophthalmol 2011; 95: 518-23.
117. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-65.
118. Reibaldi M, Cardascia N, Longo A etal. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-15.
119. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011; 95: 514-7.
120. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010; 149: 441-6.
121. Brancato R, Scialdone A, Pece A, Coscas G, Binaghi M. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol 1987; 225: 166-8.
122. Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 2004; 4: 15. Available from http://www.biomedcentral.com/1471-2415/4/15.
123. Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008; 115: 2229-34.
124. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol 2008; 18: 934-40.
125. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2011; 249: 969-74.
126. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010; 24: 155-8.
127. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010; 35: 91-8.
128. Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol 2011; 89: e293-e294.
129. Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010; 30: 1465-71.
130. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011; 31: 1928-36.
131. Nielsen JS, Bachhawat A, Jampol LM. A case of chronic severe central serous chorioretinopathy responding to oral mifepristone: update. Retina 2008; 28: 1363.
132. Golshahi A, Klingmuller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study. Acta Ophthalmol 2010; 88: 576-81.
133. Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol 2002; 58: 382-6.
134. Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol 1998; 54: 401-4.